NCT02441062View on ClinicalTrials.gov

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 20, 2020

Study Completion Date

January 20, 2020

Conditions
Neuroendocrine TumorsCarcinoid TumorsNeuroblastomaMedulloblastoma
Interventions
DRUG

68Ga-DOTATOC PET/CT

Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

University of Iowa

OTHER

lead

Sue O'Dorisio

OTHER

NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter